(Q24240492)

1

object named as

Angela C Webster

0 references

author name string

Lorenn P Ruster

2

0 references

Richard G McGee

3

0 references

Sandra L Matheson

4

0 references

Gail Y Higgins

5

0 references

Narelle S Willis

6

0 references

Jeremy R Chapman

Cochrane Database of Systematic Reviews

7

0 references

publication date

20 January 2010

0 references

published in

0 references

cites work

CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Steroid withdrawal or steroid avoidance in renal transplant recipients: focus on tacrolimus-based immunosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Two corticosteroid-free regimens-tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil-in comparison with a standard triple regimen in renal transplantation: results of the Atlas study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

The role of the protocol biopsies in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Randomised trial of simulect versus placebo for control of acute rejection in renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Rabbit antithymocyte globulin versus basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Corticosteroid-free immunosuppression with tacrolimus, mycophenolate mofetil, and daclizumab induction in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized trial of thymoglobulin vs. alemtuzumab (with lower dose maintenance immunosuppression) vs. daclizumab in renal transplantation at 24 months of follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

B-cell-depleting induction therapy and acute cellular rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Results of 3-year phase III clinical trials with daclizumab prophylaxis for prevention of acute rejection after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Daclizumab (humanized anti-IL2Ralpha mAb) prophylaxis for prevention of acute rejection in renal transplant recipients with delayed graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Placebo-controlled study of a humanized anti-TAC monoclonal antibody in dual therapy for prevention of acute rejection after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Low rate of acute rejection and cytomegalovirus infection in kidney transplant recipients with basiliximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Results of renal transplantation with different immunosuppressive regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Weak humoral posttransplant alloresponse after a well-HLA-matched cadaveric kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Zenapax versus OKT-3 prophylaxis in immunologically high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Tacrolimus-Basiliximab versus Cyclosporine-Basiliximab in renal transplantation "de novo": acute rejection and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Safety and efficacy of an alternative basiliximab (Simulect) regimen after renal transplantation: administration of a single 40-mg dose on the first postoperative day in patients receiving triple therapy with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Bolus anti-thymocyte globulin induction in renal transplant recipients: a comparison with conventional ATG or anti-interleukin-2 receptor antibody induction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Economic analysis of basiliximab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Daclizumab versus antithymocyte globulin in high-immunological-risk renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Pharmacokinetics and immunodynamics of basiliximab in pediatric renal transplant recipients on mycophenolate mofetil comedication

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Efficacy and safety of basiliximab in pediatric renal transplant patients receiving cyclosporine, mycophenolate mofetil, and steroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine a monotherapy in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Pharmacokinetics of daclizumab and mycophenolate mofetil with cyclosporine and steroids in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Preliminary results of a prospective randomized study of basiliximab in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab significantly reduces acute rejection in renal transplant patients given triple therapy with azathioprine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Pharmacoeconomic evaluation of Simulect prophylaxis in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab combined with low-dose rabbit anti-human thymocyte globulin: a possible further step toward effective and minimally toxic T cell-targeted therapy in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Two-hour post-dose cyclosporine level is a better predictor than trough level of acute rejection of renal allografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

An economic and quality-of-life assessment of basiliximab vs antithymocyte globulin immunoprophylaxis in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Reduced exposure to calcineurin inhibitors in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Clinical rejection and persistent immune regulation in kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Tacrolimus dose requirement in renal transplant recipients is significantly higher when used in combination with corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

The influence of corticosteroids on quantitative ultrasound parameters of the calcaneus in the 1st year after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

No important influence of limited steroid exposure on bone mass during the first year after renal transplantation: a prospective, randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Steroid-withdrawal at 3 days after renal transplantation with anti-IL-2 receptor alpha therapy: a prospective, randomized, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

ATG versus basiliximab induction therapy in renal allograft recipients receiving a dual immunosuppressive regimen: one-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Evaluation of daclizumab to reduce delayed graft function in non-heart-beating renal transplantation: a prospective, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Randomized clinical trial of daclizumab induction and delayed introduction of tacrolimus for recipients of non-heart-beating kidney transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized trial of basiliximab with three different patterns of cyclosporin A initiation in renal transplant from expanded criteria donors and at high risk of delayed graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Can acute rejection be prevented in SPK transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

De novo kidney transplantation without use of calcineurin inhibitors preserves renal structure and function at two years.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized, multicenter study of steroid avoidance, early steroid withdrawal or standard steroid therapy in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Long-term efficacy and safety of a calcineurin inhibitor-free regimen in live-donor renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Graft function, cardiovascular risk factors, and sex hormones in renal transplant recipients on an immunosuppressive regimen of everolimus, reduced dose of cyclosporine, and basiliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Daclizumab induction/tacrolimus sparing: a randomized prospective trial in renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Incidence of PTLD in pediatric renal transplant recipients receiving basiliximab, calcineurin inhibitor, sirolimus and steroids.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

A randomized exploratory trial of steroid avoidance in renal transplant patients treated with everolimus and low-dose cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Renal function with delayed or immediate cyclosporine microemulsion in combination with enteric-coated mycophenolate sodium and steroids: results of follow up to 30 months post-transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Assessment of two strategies of neoral administration, early versus delayed, on renal function and efficacy in de novo renal transplant patients receiving myfortic, steroids, and anti-IL2R antibodies: 12-month results of a randomized, multicentre, o

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Tolerability of Enteric-Coated Mycophenolate Sodium to 1 Year in Combination With Cyclosporine and Corticosteroids in Renal Transplant Recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Efficacy and safety of enteric-coated mycophenolate sodium in de novo renal transplant recipients: pooled data from three 12-month multicenter, open-label, prospective studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Untreated rejection in 6-month protocol biopsies is not associated with fibrosis in serial biopsies or with loss of graft function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Short-term anti-CD25 monoclonal antibody treatment and neogenetic CD4(+)CD25(high) regulatory T cells in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Role of anti-interleukin-2 receptor antibodies in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Balancing benefits and harms in health care.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

The cost-effectiveness of induction immunosuppression in kidney transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Anti-interleukin-2 receptor antibodies: basiliximab and daclizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Tailoring immunosuppressive therapy for renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Interleukin 2 receptor antagonists for kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Statistical Methods for Examining Heterogeneity and Combining Results from Several Studies in Meta-Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

Basiliximab induction therapy for live donor kidney transplantation: a long-term follow-up of prospective randomized controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD003897.PUB3

High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation

21 January 2018

1 reference

12 December 2020

Screening for basiliximab exposure-response relationships in renal allotransplantation

1 reference

12 December 2020

Daclizumab prevents acute rejection and improves patient survival post transplantation: 1 year pooled analysis

1 reference

12 December 2020

Antithymocyte globulin versus basiliximab in renal transplantation

1 reference

12 December 2020

Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR Study

1 reference

12 December 2020

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

12 December 2020

Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients

1 reference

12 December 2020

Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts

1 reference

12 December 2020

Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: a clinical study

1 reference

12 December 2020

Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients

1 reference

12 December 2020

Kidney Transplantation With Sirolimus and Mycophenolate Mofetil???Based Immunosuppression: 5-Year Results of a Randomized Prospective Trial Compared to Calcineurin Inhibitor Drugs

1 reference

12 December 2020

Differential IL-2 receptor expression in renal allograft recipients treated with an anti-IL-2-receptor antibody

1 reference

12 December 2020

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

12 December 2020

Long-term follow-up after induction treatment with monoclonal anti-interleukin-2 receptor antibody (BT563) in kidney allograft recipients: a double-blind, placebo-controlled trial

1 reference

12 December 2020

Simulect (basiliximab) reduces acute cellular rejection in renal allografts from cadaveric and living donors

1 reference

12 December 2020

Prophylactic use of monoclonal anti-IL-2 receptor antibody in cadaveric renal transplantation

1 reference

12 December 2020

Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal antibody. II. Results after a second kidney transplantation

1 reference

12 December 2020

Anti-IL2 receptor monoclonal antibody (33B3.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin

1 reference

12 December 2020

Daclizumab: outcome of phase III trials and mechanism of action. Double Therapy and the Triple Therapy Study Groups

1 reference

12 December 2020

Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.

1 reference

12 December 2020

Interleukin 2 receptor blockers may directly inhibit lymphocyte mediated ischaemia reperfusion injury

1 reference

12 December 2020

Cost-minimization study comparing Simulect versus Thymoglobulin in renal transplant induction

1 reference

12 December 2020

A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation

1 reference

12 December 2020

Immunosuppressive agents in organ transplantation: past, present, and future

1 reference

12 December 2020

Activated protein C reduces graft neutrophil activation in clinical renal transplantation

1 reference

12 December 2020

Serum sCD30 in monitoring of alloresponse in well HLA-matched cadaveric kidney transplantations

1 reference

12 December 2020

1 reference

12 December 2020

Economic Implications of the Use of Basiliximab in Addition to Triple Immunosuppressive Therapy in Renal Allograft Recipients

1 reference

12 December 2020

A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation

1 reference

12 December 2020

Long-term results of rabbit antithymocyte globulin and basiliximab induction

1 reference

12 December 2020

12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients

1 reference

12 December 2020

Renal function with cyclosporine C2 monitoring, enteric-coated mycophenolate sodium and basiliximab: a 12-month randomized trial in renal transplant recipients

1 reference

12 December 2020

Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients

1 reference

12 December 2020

A double-blind, placebo-controlled study of monoclonal anti-interleukin-2 receptor antibody (BT563) administration to prevent acute rejection after kidney transplantation

1 reference

12 December 2020

Association of graft neutrophil sequestration with delayed graft function in clinical renal transplantation

1 reference

12 December 2020

A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience

1 reference

12 December 2020

ATG-Fresenius or daclizumab induction therapy in immunologically high risk kidney recipients: a prospective randomized pilot trial

1 reference

12 December 2020

Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study

1 reference

12 December 2020

Long-term results of monoclonal anti-Il2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantation

1 reference

12 December 2020

Early experience with anti-Tac in clinical renal transplantation

1 reference

12 December 2020

Correlation between oxidative stress and immunosuppressive therapy in renal transplant recipients with an uneventful postoperative course and stable renal function

1 reference

12 December 2020

Decreased renal excretion of soluble interleukin-2 receptor alpha after treatment with daclizumab

1 reference

12 December 2020

Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study

1 reference

12 December 2020

Zenapax (daclizumab) reduces the incidence of acute rejection episodes and improves patient survival following renal transplantation. No 14874 and No 14393 Zenapax Study Groups

1 reference

12 December 2020

A randomized prospective trial of anti-Tac monoclonal antibody in human renal transplantation

1 reference

12 December 2020

Daclizumab (Zenapax) inhibits early interleukin-2 receptor signal transduction events

1 reference

12 December 2020

Cytokines and growth factors serum level and renal allograft function (preliminary report)

1 reference

12 December 2020

A prospective economic evaluation of basiliximab (Simulect) therapy following renal transplantation

1 reference

12 December 2020

Prophylactic use of the IL-2 receptor-specific monoclonal antibody LO-Tact-1 with cyclosporin A and steroids in renal transplantation

1 reference

12 December 2020

Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study Group

1 reference

12 December 2020

Single bolus antithymocyte globulin versus basiliximab induction in kidney transplantation with cyclosporine triple immunosuppression: efficacy and safety

1 reference

12 December 2020

Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantation. The U.S. Simulect Renal Transplant Study Group

1 reference

12 December 2020

The effect of anti-CD25 monoclonal antibody (Simulect) to the lymphocytes in the peripheral blood of the recipients of kidney transplantation

1 reference

12 December 2020

Long-term results (10 years) of a prospective trial comparing Lo-tact-1 monoclonal antibody and anti-thymocyte globulin induction therapy in kidney transplantation

1 reference

12 December 2020

Cytomegalovirus infections after treatment with daclizumab, an anti IL-2 receptor antibody, for prevention of renal allograft rejection. Roche Study Group

1 reference

12 December 2020

Basiliximab reduces the incidence of acute cellular rejection in live-related-donor kidney transplantation: a three-year prospective randomized trial.

1 reference

12 December 2020

Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group

1 reference

12 December 2020

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group

1 reference

12 December 2020

Prospective randomised trial of the use of Daclizumab in renal transplantation using kidneys from non heart beating donors

1 reference

12 December 2020

Impact of early or delayed cyclosporine on delayed graft function in renal transplant recipients: a randomized, multicenter study

1 reference

12 December 2020

In vivo anti-interleukin-2 receptor (anti-Tac) therapy is immunosuppressive, but not tolerogenic

1 reference

12 December 2020

Reduced-exposure cyclosporine is safe and efficacious in de novo renal transplant recipients treated with enteric-coated mycophenolic acid and basiliximab.

1 reference

12 December 2020

How to identify randomized controlled trials in MEDLINE: ten years on

1 reference

12 December 2020

Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.

1 reference

12 December 2020

Rabbit antithymocyte globulin or basiliximab for induction therapy?

1 reference

12 December 2020